Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients
21 June 2018 - 9:30PM
Syneos Health™ (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, and Elligo Health
Research, the only platform that brings clinical research direct to
clinical health care, are entering a strategic collaboration to
mobilize a system of accelerated research to reach real-world
patients. Both companies share a vision to evolve the clinical
trial paradigm to speed the delivery of biopharmaceutical therapies
to market.
Syneos Health is a top three Contract Research Organization
(CRO) that combines comprehensive and integrated outsourcing
solutions for both clinical development and commercialization.
Elligo Health Research deploys an approach that improves clinical
trial access by engaging the 97 percent of physicians currently not
offering clinical research to their patients.
Applying its Goes Direct® approach, Elligo identifies patients
for clinical trials using electronic health records and then
provides their physicians with the infrastructure to conduct the
research in their own practices. This platform enables research at
practices that historically would not have had the infrastructure
to conduct clinical research. Syneos Health will collaborate with
Elligo to pilot new ways of quickly finding patients to enlist them
in clinical trial research.
The collaboration will seek to build a centrally managed
infrastructure and regulatory research system around physicians and
patients who have not typically been accessible in traditional
sites. This could include deploying expert staff and providing the
training and regulatory guidance needed to run a trial, removing
physician burden and focusing the experience around the
patient.
The ability to bring clinical research to underrepresented
populations through community medical practices, evolving from a
location-bound approach, to a centrally managed systemic approach,
redefines the clinical trial site footprint. This effort should
improve quality, reduce timelines and save costs.
“Our biopharma acceleration model is designed to completely
surround the patient, caregiver or any stakeholder with the most
relevant solutions to make the clinical trial process easier and
more accessible. Our collaboration with Elligo allows us to do just
that,” said Alistair Macdonald, chief executive officer, Syneos
Health. “By leveraging data, technology and trusted physician
relationships, we believe we can radically reduce enrollment times
and impact health outcomes on behalf of our customers.”
“We are thrilled to collaborate with Syneos Health to create a
system of accelerated research that expands our vision of engaging
the patient and physician in clinical research,” said John
Potthoff, Ph.D., chief executive officer, Elligo. “Not only are we
maximizing clinical trial process efficiencies, we’re transforming
the clinical trial paradigm with deeper insights and more
actionable real-world evidence.” To learn more about how
Syneos Health and Elligo are advancing clinical research, visit
syneoshealth.com and elligodirect.com. Also, sign up to receive
information about the 2019 Bridging Clinical Research and Clinical
Health Care Collaborative, an event sponsored by Syneos Health
and Elligo to strengthen the connection between clinical research
and health care.
About Syneos HealthSyneos
Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical
solutions organization. Our company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. Created through the merger of two industry
leading companies – INC Research and inVentiv Health – we bring
together more than 21,000 clinical and commercial minds with the
ability to support customers in more than 110 countries. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients. To learn more about how we are
shortening the distance from lab to
life® visit syneoshealth.com.
About ElligoElligo Health Research offers
the only platform that brings clinical research to physician
practices, accelerating the development of new pharmaceutical,
biotechnology and medical device products and therapies.
Our Goes Direct® approach uses state-of-the-art technology to
compliantly leverage current electronic health record data and
applies a proprietary, prescreening process to match
protocol-eligible patients for participation in clinical studies.
It is our mission to support health care providers by providing
personnel, procedures, technology and infrastructure for clinical
research, enabling patients to participate in research while
remaining under the care of their own trusted physician. Learn more
at elligodirect.com.
Forward-Looking StatementsExcept for historical
information, all of the statements, expectations, and assumptions
contained in this press release are forward-looking statements as
that term is defined in the Private Securities Litigation Reform
Act of 1995. Actual results might differ materially from those
explicit or implicit in the forward-looking statements. Important
factors that could cause actual results to differ materially
include, but are not limited to: risks associated with the
integration of the Company's business with the business of inVentiv
Health and its operation of the combined business following the
closing of the Merger; the Company's ability to maintain or
generate new business awards; the Company's ability to increase its
market share, grow its business, and execute its growth strategies;
the Company's backlog not being indicative of future revenues and
its ability to realize the anticipated future revenue reflected in
its backlog; the impact of adoption of the new accounting standard
of recognizing revenue from customers; the impact of the Tax Act;
the Company's ability to adequately price its contracts and not
overrun cost estimates; general and international economic,
political, and other risks, including currency and stock market
fluctuations and the uncertain economic environment; fluctuations
in the Company's financial results; reliance on key personnel;
customer or therapeutic area concentration; and the other risk
factors set forth in the Company's Annual Report on Form 10-K for
the fiscal year ended December 31, 2017 and
other SEC filings, copies of which are available free of
charge on the Company's website
at investor.syneoshealth.com. Syneos Health assumes
no obligation and does not intend to update these forward-looking
statements, except as required by law.
CONTACTS:
Lea StuderElligo Health Research+1 402 366
1752lea@scorrmarketing.com
Danielle DeForgeSyneos Health+1 202 210
5992danielle.deforge@syneoshealth.com
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024